Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(7):534-538; doi:10.1093/jnci/93.7.534
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cook, R. J.
Right arrow Articles by Major, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cook, R. J.
Right arrow Articles by Major, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 7, 534-538, April 4, 2001
© 2001 Oxford University Press

REPORT

Methodology for Treatment Evaluation in Patients With Cancer Metastatic to Bone

Richard J. Cook, Pierre Major

Affiliations of authors: R. J. Cook, Department of Statistics and Actuarial Science, University of Waterloo, ON, Canada; P. Major, Hamilton Regional Cancer Centre and Department of Medicine, McMaster University, ON.

Correspondence to: Pierre Major, M.D., Hamilton Regional Cancer Center, 699 Concession St., Hamilton, ON, Canada L8V 5C2.

Background: Patients with cancer metastatic to bone experience several adverse and clinically important skeletal-related events, including pathologic fractures, vertebral compressions with fracture, the need for surgery to treat or prevent fractures, and the need for radiation therapy for the treatment of bone pain. We present appropriate methods for describing and modeling the clinical course of skeletal-related events and comparing treatments for such events. Methods: On the basis of data from a recently completed randomized, placebo-controlled trial involving 380 breast cancer patients with bone metastases, we tested the validity of the "events-per-person-years" method, one of the most commonly used techniques, for the analysis of skeletal-related events. We then used more robust methods of analysis that are based on fewer assumptions, including a random-effects Poisson model, and contrasted the inferences about skeletal-related event rates and treatment effects for the different analytic methods. All statistical tests were two-sided. Results: The events-per-person-years analysis underestimated substantially the variation in the data and is not appropriate to summarize the incidence rate of skeletal-related events. A random-effects Poisson model did provide a valid basis for analyzing such data. Conclusions: The underestimation of variability in data associated with the use of the events-per-person-years analysis leads to unduly narrow confidence intervals for complication rates and inflated false-positive error rates in treatment comparisons. A random-effects Poisson model provides a valid, robust basis for describing the clinical course of bone complications and evaluating treatment effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken
Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
Oncologist, February 1, 2009; 14(2): 181 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Cook and P. Major
Multistate analysis of skeletal events in patients with bone metastases.
Clin. Cancer Res., October 15, 2006; 12(20): 6264s - 6269s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski
Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer
J. Clin. Oncol., December 1, 2003; 21(23): 4277 - 4284.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. S. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh, M. Krzakowski, M. Pawlicki, P. de Souza, M. Zheng, G. Urbanowitz, et al.
Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial--The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
J. Clin. Oncol., August 15, 2003; 21(16): 3150 - 3157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol., September 1, 2002; 20(17): 3719 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Stat Methods Med ResHome page
R J Cook and J F Lawless
Analysis of repeated events
Statistical Methods in Medical Research, April 1, 2002; 11(2): 141 - 166.
[Abstract] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. J. Glynn and J. E. Buring
Counting Recurrent Events in Cancer Research
J Natl Cancer Inst, April 4, 2001; 93(7): 488 - 489.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.